MX2009004081A - Metodo para restaurar el efecto de incretina. - Google Patents

Metodo para restaurar el efecto de incretina.

Info

Publication number
MX2009004081A
MX2009004081A MX2009004081A MX2009004081A MX2009004081A MX 2009004081 A MX2009004081 A MX 2009004081A MX 2009004081 A MX2009004081 A MX 2009004081A MX 2009004081 A MX2009004081 A MX 2009004081A MX 2009004081 A MX2009004081 A MX 2009004081A
Authority
MX
Mexico
Prior art keywords
restoring
methods
present
insulin secretion
incretin effect
Prior art date
Application number
MX2009004081A
Other languages
English (en)
Inventor
Anton H Clemens
Original Assignee
Cpd Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cpd Llc filed Critical Cpd Llc
Publication of MX2009004081A publication Critical patent/MX2009004081A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con métodos para tratar el síndrome metabólico, diabetes mellitus Tipo II, dislipidemia aterogénica y/u obesidad. La presente invención también se relaciona con métodos para restaurar el efecto de incretina, para restaurar el control fisiológico de niveles de glucagón, para restaurar la secreción de insulina de primera fase y restaurar la secreción de insulina dependiente de glucosa fisiológica. Los métodos de la presente invención comprenden la administración de un antagonista ic-receptor selectivo, tal como naltrindol guanidinilatado (GLTI), o derivados farmacéuticamente aceptados de los mismos a un sujeto con necesidad de los mismos.
MX2009004081A 2006-10-20 2007-10-22 Metodo para restaurar el efecto de incretina. MX2009004081A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86222706P 2006-10-20 2006-10-20
PCT/US2007/082084 WO2008051902A2 (en) 2006-10-20 2007-10-22 Method of restoring the incretin effect

Publications (1)

Publication Number Publication Date
MX2009004081A true MX2009004081A (es) 2009-06-18

Family

ID=39325299

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004081A MX2009004081A (es) 2006-10-20 2007-10-22 Metodo para restaurar el efecto de incretina.

Country Status (9)

Country Link
US (8) US7893080B2 (es)
EP (2) EP2724722B1 (es)
BR (1) BRPI0718420A2 (es)
CA (1) CA2666846C (es)
ES (1) ES2618500T3 (es)
MX (1) MX2009004081A (es)
PT (1) PT2724722T (es)
SI (1) SI2724722T1 (es)
WO (1) WO2008051902A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2618500T3 (es) * 2006-10-20 2017-06-21 Neurendo Pharma, Llc Método para restaurar el efecto incretina
EP2509949B1 (en) * 2009-12-07 2014-04-23 University Of Georgia Research Foundation, Inc. Pyridinone hydroxycyclopentyl carboxamides: hiv integrase inhibitors with therapeutic applications
EP3215154B1 (en) 2014-11-07 2020-01-29 Regents of the University of Minnesota Salts and compositions useful for treating disease

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272540A (en) 1979-04-24 1981-06-09 Sisa, Incorporated 14-Methoxymorphinan-6-one compounds and therapeutic methods of treating pain and drug dependence with them
AU538186B2 (en) 1980-03-07 1984-08-02 Scotia Holdings Plc Prostaglandin precursors
US4451470A (en) 1982-07-06 1984-05-29 E. I. Du Pont De Nemours And Company Analgesic, antagonist, and/or anorectic 14-fluoromorphinans
HU201675B (en) 1983-08-26 1990-12-28 Ivan Balkanyi Process for producing oral pharmaceutical compositions with unappetizing effect
US4478840A (en) 1983-10-11 1984-10-23 E. I. Du Pont De Nemours And Company Appetite suppressing compositions and methods
US5208250A (en) 1988-05-25 1993-05-04 Warner-Lambert Company Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents
US4882335A (en) 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US5428066A (en) 1989-03-08 1995-06-27 Larner; Joseph Method of reducing elevated blood sugar in humans
US5843089A (en) 1990-12-28 1998-12-01 Boston Scientific Corporation Stent lining
US5674192A (en) * 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US5086058A (en) 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
WO1993000337A1 (de) * 1991-06-21 1993-01-07 Dr. Karl Thomae Gmbh (s)(+)-2-äthoxy-4-[n-[1-(2-piperidino-phenyl)-3-methyl-1-butyl]aminocarbonylmethyl]-benzoesäure
US5866595A (en) 1991-09-26 1999-02-02 The Regents Of The University Of California Calcium antagonists for treatment of vascular restenosis
DE4136215A1 (de) 1991-11-02 1993-05-06 Ferring Arzneimittel Gmbh, 2300 Kiel, De Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie
US5665383A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5772629A (en) 1995-10-23 1998-06-30 Localmed, Inc. Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
WO1997018781A1 (en) 1995-11-20 1997-05-29 University Of Miami Method of treating nicotine dependence
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
GB9606076D0 (en) 1996-03-22 1996-05-22 Univ Birmingham Diabetes treatment
US5891909A (en) * 1996-03-29 1999-04-06 3-Dimensional Pharmaceuticals, Inc. Amidinohydrazones as protease inhibitors
US6294559B1 (en) * 1996-05-02 2001-09-25 Merck & Co., Inc. Antiproliferative agents associated with peroxisome proliferator activated receptors gamma1 and gamma2
US6387121B1 (en) * 1996-10-21 2002-05-14 Inflow Dynamics Inc. Vascular and endoluminal stents with improved coatings
US5878750A (en) 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US6026817A (en) 1996-11-14 2000-02-22 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US5727570A (en) 1996-11-14 1998-03-17 Clemens; Anton H. Method of treating hyperlipidemia in humans
US5925657A (en) 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
US6103722A (en) 1997-07-23 2000-08-15 The Medical College Of Wisconsin Research Foundation Inc. Ischemic preconditioning
US6242196B1 (en) 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
AU736951C (en) 1998-03-19 2003-02-20 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
WO1999058120A1 (en) 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
US6280411B1 (en) * 1998-05-18 2001-08-28 Scimed Life Systems, Inc. Localized delivery of drug agents
AU3809999A (en) 1998-05-18 1999-12-06 Novo Nordisk A/S Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
US6369039B1 (en) 1998-06-30 2002-04-09 Scimed Life Sytems, Inc. High efficiency local drug delivery
US6500824B1 (en) 1998-08-06 2002-12-31 Regents Of The University Of Minnesota Kappa (OP2) opioid receptor antagonists
WO2000024730A1 (en) 1998-10-28 2000-05-04 The University Of British Columbia Organic vanadium(iii) complexes and their use
US6087385A (en) * 1998-10-30 2000-07-11 University Of Mississippi Flavonoid derivatives
US6419692B1 (en) * 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
MXPA01009893A (es) * 1999-04-01 2003-07-28 Esperion Therapeutics Inc Compuestos con eter, composiciones y usos de estos.
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6258121B1 (en) * 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6309660B1 (en) * 1999-07-28 2001-10-30 Edwards Lifesciences Corp. Universal biocompatible coating platform for medical devices
US6471979B2 (en) * 1999-12-29 2002-10-29 Estrogen Vascular Technology, Llc Apparatus and method for delivering compounds to a living organism
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US20020045572A1 (en) * 2000-08-15 2002-04-18 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
WO2002013759A2 (en) * 2000-08-15 2002-02-21 Cpd Llc Method of treating the syndrome of type 2 diabetes in humans
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6910310B2 (en) 2002-09-03 2005-06-28 Braided Accents Llc Chair rail system and method
ES2618500T3 (es) 2006-10-20 2017-06-21 Neurendo Pharma, Llc Método para restaurar el efecto incretina

Also Published As

Publication number Publication date
US8829018B2 (en) 2014-09-09
PT2724722T (pt) 2017-03-14
US8399474B2 (en) 2013-03-19
US20080108640A1 (en) 2008-05-08
BRPI0718420A2 (pt) 2013-11-12
ES2618500T3 (es) 2017-06-21
WO2008051902A3 (en) 2008-07-10
CA2666846A1 (en) 2008-05-02
US20130172380A1 (en) 2013-07-04
US20150065535A1 (en) 2015-03-05
EP2724722B1 (en) 2016-12-07
US8445508B2 (en) 2013-05-21
EP2083817A2 (en) 2009-08-05
US7893080B2 (en) 2011-02-22
CA2666846C (en) 2018-04-10
US20130224176A1 (en) 2013-08-29
US20110034501A1 (en) 2011-02-10
SI2724722T1 (sl) 2017-07-31
US20190134023A1 (en) 2019-05-09
EP2083817A4 (en) 2009-12-23
US20110118293A1 (en) 2011-05-19
US20140329844A1 (en) 2014-11-06
US9987268B2 (en) 2018-06-05
EP2724722A1 (en) 2014-04-30
WO2008051902A2 (en) 2008-05-02
US8785469B2 (en) 2014-07-22

Similar Documents

Publication Publication Date Title
UA89615C2 (ru) Фармацевтические композиции, которые содержат никотиновую кислоту и антагонист рецептора dp
WO2006086107A3 (en) Methods and compositions for minimizing accrual of inhalable insulin in the lungs
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2004056317A3 (en) Compositions for the treatment and prevention of nephropathy
Henry et al. Mechanism and management of hyperglycemia associated with pasireotide: results from studies in healthy volunteers
WO2007048026A3 (en) Cgrp peptide antagonists and conjugates
TNSN07080A1 (en) Method of assembly of drug delivery devices
WO2004000354A3 (en) Method of treating the syndrome of lipodystrophy
MXPA05006994A (es) Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina.
IL168056A0 (en) Selected cgrp antagonists, method for production and use thereof as medicament
MX2008013304A (es) Compuestos de peptido 1 tipo glucagon.
EP1143989A3 (en) Methods for glucagon suppression
PL376373A1 (en) Selected cgrp antagonists, method for production and use thereof as medicament
WO2005123109A3 (en) Pegylation of vasoactive intestinal peptide (vip)/pituitary adenylate cyclase activating peptide (pacap) receptor 2 (vpac2) agonists and methods of use
WO2006047392A3 (en) Nicotinic-opioid synergy for analgesia
WO2004050115A3 (en) Combination treatment using exendin-4 and thiazolidinediones
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
CY1110152T1 (el) Χρηση συνδυασμου μορφινης και τουλαχιστον ενος ανταγωνιστη φυσικου οπιοειδους στην αγωγη της εξαρτησης απο φυσικα οπιοειδη και στην προληψη της μη στοματικης καταχρησης φυσικων οπιοειδων σε εξαρτημενους απο φυσικα οπιοειδη
MX2009004081A (es) Metodo para restaurar el efecto de incretina.
WO2005067548A3 (en) Use of ribose in recovery from anaesthesia
AU2012207301A8 (en) Apolipoprotein AIV as an antidiabetic peptide
HK1106447A1 (en) Liquid allergy vaccine formulation for oromucosal administration

Legal Events

Date Code Title Description
HH Correction or change in general
GB Transfer or rights
FG Grant or registration